We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VOYG
826
Voyager Technologies
VOYG
$1.66B
| $785K | ﹤0.01% |
+20,000
| New | +$954K |
|
827
MGM Resorts International
MGM
$11.4B
| $768K | ﹤0.01% |
22,345
+3,444
| +18% | +$109K |
|
828
PepGen
PEPG
$130M
| $768K | ﹤0.01% |
691,530
-89,367
| -11% | -$126K |
|
829
Invesco
IVZ
$13.6B
| $762K | ﹤0.01% |
48,351
+10,501
| +28% | +$151K |
|
830
Ericsson
ERIC
$33.1B
| $761K | ﹤0.01% |
+89,762
| New | +$738K |
|
831
Fox Class B
FOX
$22.1B
| $737K | ﹤0.01% |
14,271
+3,126
| +28% | +$152K |
|
832
Core Scientific
CORZ
$7.34B
| $710K | ﹤0.01% |
+41,566
| New | +$416K |
|
|
BOW
833
Bowhead Specialty Holdings
BOW
$1.11B
| $706K | ﹤0.01% |
18,820
+4,872
| +35% | +$187K |
|
|
DAWN
834
DELISTED
Day One Biopharmaceuticals
DAWN
| $653K | ﹤0.01% |
100,516
-112,638
| -53% | -$775K |
|
835
Campbell Soup
CPB
$6.67B
| $652K | ﹤0.01% |
21,287
+4,664
| +28% | +$164K |
|
836
Caesars Entertainment
CZR
$6.06B
| $638K | ﹤0.01% |
22,468
+4,516
| +25% | +$123K |
|
837
AtaiBeckley Inc
ATAI
$2.66B
| $637K | ﹤0.01% |
290,943
+8,758
| +3% | +$15.7K |
|
838
Korro Bio
KRRO
$155M
| $626K | ﹤0.01% |
50,094
| – | – |
|
839
Zentalis Pharmaceuticals
ZNTL
$331M
| $615K | ﹤0.01% |
530,582
| – | – |
|
840
Gossamer Bio
GOSS
$84.9M
| $609K | ﹤0.01% |
495,153
-233,306
| -32% | -$254K |
|
841
Gen Digital
GEN
$16.9B
| $600K | ﹤0.01% |
20,395
-7,195
| -26% | -$197K |
|
842
InflaRx
IFRX
$258M
| $594K | ﹤0.01% |
751,267
+283
| +0% | +$335 |
|
843
PAR Technology
PAR
$715M
| $590K | ﹤0.01% |
+8,509
| New | +$532K |
|
844
NETSCOUT
NTCT
$2.98B
| $582K | ﹤0.01% |
+23,460
| New | +$521K |
|
845
IDEX
IEX
$17.2B
| $581K | ﹤0.01% |
+3,311
| New | +$587K |
|
|
ALMS
846
Alumis Inc
ALMS
$3.33B
| $577K | ﹤0.01% |
+192,490
| New | +$909K |
|
847
Enphase Energy
ENPH
$5.2B
| $562K | ﹤0.01% |
14,175
+2,984
| +27% | +$138K |
|
848
Altimmune
ALT
$583M
| $553K | ﹤0.01% |
+142,863
| New | +$773K |
|
849
WIX.com
WIX
$2.38B
| $551K | ﹤0.01% |
3,480
+1,188
| +52% | +$191K |
|
850
TriNet
TNET
$3.24B
| $547K | ﹤0.01% |
7,475
-56,228
| -88% | -$4.46M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.